GLP-1 Weight-Loss and Diabetes Drug Lawsuits: Understanding the Federal Multidistrict Litigation

GLP-1 receptor agonists — a class of medications that includes drugs prescribed for type 2 diabetes and weight management — have become some of the most widely used prescription medications in the United States. Millions of people take them. Alongside their popularity, lawsuits have been filed alleging that some patients suffered serious gastrointestinal injuries, including gastroparesis (sometimes called stomach paralysis) and bowel obstruction, and that manufacturers did not adequately warn about those risks.

In February 2024, the federal Judicial Panel on Multidistrict Litigation consolidated many of these lawsuits into a single multidistrict litigation (MDL) in the U.S. District Court for the Eastern District of Pennsylvania. This article explains what the litigation involves, how MDLs work, and what patients should consider.

What Are GLP-1 Medications?

GLP-1 receptor agonists mimic a hormone called glucagon-like peptide-1, which helps regulate blood sugar and appetite. Among their effects, they slow the rate at which the stomach empties. That effect contributes to a feeling of fullness and helps with blood sugar control, and it is also related to gastrointestinal side effects such as nausea, vomiting and constipation.

Product labeling has long described common gastrointestinal side effects. The lawsuits focus on whether more serious and lasting injuries occurred, whether they were caused by the medications, and whether patients and doctors were adequately warned.

The Injuries Alleged in the Litigation

Plaintiffs in the GLP-1 litigation have alleged a range of injuries. Among the most frequently discussed are:

Gastroparesis, a condition in which the stomach empties too slowly, causing persistent nausea, vomiting, abdominal pain and malnutrition
Intestinal obstruction or ileus, a blockage or failure of normal movement in the intestines
Severe, persistent vomiting leading to complications such as dehydration and esophageal injury
Other gastrointestinal complications requiring hospitalization or surgery

Some claims have also involved other alleged injuries, and the scope of the litigation can evolve over time as courts address which injuries are included.

What Is Multidistrict Litigation?

When many similar lawsuits are filed in federal courts around the country, the Judicial Panel on Multidistrict Litigation can transfer them to a single judge for coordinated pretrial proceedings. This process is called multidistrict litigation, or MDL.

MDLs are designed to improve efficiency. Instead of dozens of judges overseeing duplicate discovery and ruling on the same issues, one judge handles shared questions such as:

Document production from manufacturers
Depositions of company witnesses
Expert testimony on general causation — whether a drug can cause a particular injury
Legal issues such as preemption and the adequacy of warnings

MDLs Are Not Class Actions

An important distinction: in an MDL, each plaintiff keeps an individual lawsuit. Each person's case depends on their own medical history, diagnosis, treatment and damages. If cases are resolved, they may be resolved individually or through a global settlement program, but each claimant's circumstances still matter. In a class action, by contrast, a representative case is brought on behalf of a group.

Bellwether Trials

Many MDLs use bellwether trials — representative cases tried before juries to test the strength of arguments on each side. Bellwether outcomes can influence settlement discussions, though they do not determine the result of other cases.

Cases Return Home

If cases are not resolved during the MDL, they may be sent back to the federal courts where they were originally filed for trial.

Key Legal Issues in Pharmaceutical Cases

Drug injury claims typically involve several recurring legal questions.

Causation

Plaintiffs must show that the drug can cause the alleged injury (general causation) and that it did cause their injury (specific causation). This usually requires expert testimony and careful review of medical records, including whether other conditions or medications could explain the symptoms.

Failure to Warn

Many pharmaceutical claims allege that the manufacturer knew or should have known about a risk and failed to adequately warn doctors and patients. Under the "learned intermediary" doctrine followed in many states, the manufacturer's duty to warn generally runs to the prescribing doctor, who is expected to weigh the risks and benefits for the patient.

Preemption

Drug manufacturers often argue that federal law governing drug labeling prevents state-law failure-to-warn claims. Courts evaluate whether the manufacturer could have changed its label under federal regulations and whether there is clear evidence that the FDA would have rejected a different warning.

Diagnosis Documentation

For gastrointestinal claims, how a condition was diagnosed matters. Gastroparesis, for example, may be confirmed with a gastric emptying study. Courts in drug litigation often address what level of diagnostic evidence is required.

What Patients Should Know

Do Not Stop Taking Medication Without Medical Advice

GLP-1 medications treat serious conditions. Stopping a medication abruptly can have health consequences. Any concerns about side effects should be discussed with your prescribing physician.

Keep Detailed Records

If you have experienced serious gastrointestinal symptoms while taking a GLP-1 medication, keep a record of:

Which medication you took, the dose, and the dates you started and stopped
Pharmacy records and prescription history
When symptoms began and how they progressed
Emergency room visits, hospitalizations and procedures
Diagnostic tests such as gastric emptying studies, imaging or endoscopy
Time missed from work and other expenses

Understand Compounded Products

During periods of drug shortages, some patients received compounded versions of GLP-1 medications. Claims involving compounded products may raise different legal questions than claims involving brand-name products, including which company is responsible.

Deadlines Still Apply

Being part of a mass tort does not suspend your individual statute of limitations. Deadlines vary by state and may begin when you knew or should have known about your injury and its possible connection to a medication.

The Broader Context of Drug Injury Litigation

Pharmaceutical litigation has a long history in the United States. Lawsuits have played a role in uncovering safety information, prompting label changes and compensating injured patients. They have also been criticized for creating uncertainty about medications with real benefits. Both perspectives are part of a larger conversation about how drug safety is monitored after approval.

The FDA continues to monitor safety data on approved drugs through adverse event reporting and other systems. Labels may be updated as new information emerges. Patients and doctors can report suspected side effects to the FDA's MedWatch program.

How Mass Tort Claims Are Evaluated

When we review a potential drug injury claim, we generally consider:

Proof of use — prescription and pharmacy records showing which product was taken and when
Diagnosis — medical documentation of a qualifying injury
Timing — whether the injury occurred during or after use in a way consistent with the alleged risk
Alternative explanations — other medical conditions or medications that could explain the injury
Damages — the medical treatment required, lasting effects, lost income and other losses
Deadlines — the statute of limitations that applies in your state

This evaluation helps determine whether a claim may be viable and how it might proceed.

Understanding Gastroparesis

Because gastroparesis is one of the most frequently discussed conditions in this litigation, it is worth understanding what it is. Gastroparesis is a disorder in which the stomach takes too long to empty its contents into the small intestine, without a physical blockage explaining the delay. Symptoms can include nausea, vomiting (sometimes of food eaten hours earlier), early fullness, bloating, abdominal pain, poor appetite and weight loss. Severe cases can cause dehydration, malnutrition, and difficulty managing blood sugar.

Gastroparesis has many potential causes. Long-standing diabetes is one of the most common, because high blood sugar over time can damage the nerves that control the stomach. Some cases follow viral infections or surgery. Some medications — including certain pain medications and other drugs — can slow stomach emptying. In some cases, no cause is identified.

This medical complexity is why causation is central in drug litigation. A plaintiff with diabetes who develops gastroparesis while taking a GLP-1 medication will face questions about whether the diabetes itself, rather than the medication, caused the condition. Medical records documenting symptoms before and after starting the medication, diagnostic testing, and the course of symptoms after stopping the drug can all be relevant.

The Diagnostic Question

Gastroparesis is typically diagnosed with a gastric emptying study, a test in which the patient eats a meal containing a small amount of a radioactive tracer while imaging tracks how quickly the stomach empties. Other tests, such as endoscopy, may be used to rule out a physical obstruction. Courts in pharmaceutical litigation have addressed whether a claim requires objective diagnostic testing or whether a clinical diagnosis based on symptoms is sufficient. How courts resolve these questions can determine which claims move forward.

For people experiencing symptoms, this underscores the importance of seeing a physician, following through with recommended testing, and keeping records. Good medical care and good documentation go hand in hand.

Other Considerations: Anesthesia and Aspiration

Medical organizations have issued guidance about GLP-1 medications and anesthesia, because slowed stomach emptying may increase the risk that stomach contents are present during procedures requiring sedation. Patients scheduled for surgery or procedures should tell their medical team about all medications they take, including GLP-1 drugs, and follow instructions about when to pause them. This is a reminder that complete medication lists help keep patients safe.

What Happens If the Litigation Resolves

Many mass torts eventually resolve through settlement programs, though some do not, and there is no way to predict the outcome of any particular litigation. When global settlements occur, they often use criteria based on the type and severity of injury, the strength of the documentation, and other factors to determine individual payment amounts. Claimants may have to submit records and meet eligibility requirements. Liens from health insurers and government programs may need to be resolved before funds are distributed.

Because each claim is individual, the outcome for one claimant may differ significantly from another's.

Frequently Asked Questions

Is there a deadline to join the GLP-1 litigation?

There is no single deadline to "join" an MDL. Each person's claim is governed by the statute of limitations in their state, which often begins when the person knew or reasonably should have known about the injury and its possible connection to the medication. Some states also have statutes of repose. Because these rules vary, it is wise to get an evaluation sooner rather than later.

Can I file a claim if I took the medication for weight loss rather than diabetes?

The reason the medication was prescribed does not by itself determine whether a claim exists. What matters is proof of use, a documented injury, and evidence connecting the two. The reason for the prescription may, however, be relevant to questions about alternative causes, such as whether long-standing diabetes contributed to a condition.

Will filing a claim affect my medical care?

No. A legal claim does not change your right to medical treatment. Your doctor's recommendations should guide your care. Your medical records, however, will be important evidence, so it helps to be thorough and honest with your providers about your symptoms.

What does it cost to pursue a claim?

Our firm handles product liability and drug injury cases on a contingency fee basis, meaning there is no attorney fee unless compensation is recovered.

Key Takeaways

Lawsuits alleging serious gastrointestinal injuries from GLP-1 medications were consolidated in a federal MDL in the Eastern District of Pennsylvania in 2024.
In an MDL, each plaintiff keeps an individual case; MDLs coordinate pretrial proceedings rather than combining claims into one.
Claims typically require proof of use, a documented diagnosis and evidence that the drug caused the injury.
Patients should not stop taking a prescribed medication without talking to their doctor.
Individual filing deadlines still apply, even when litigation is coordinated.

How We Can Help

At Personal Injury Lawyer Pro, our product liability and mass tort attorneys evaluate claims involving prescription drugs and medical devices. We review medical and pharmacy records, explain how coordinated litigation works, and help clients decide whether to pursue a claim. If you have questions about a possible drug injury, contact us for a free, confidential consultation. You pay no attorney fee unless we recover compensation for you.